Replaces Prod. #: ALX-270-271
A potent inhibitor of glycogen synthase kinase-3β (IC50=22 nM). Also inhibits CDK1 (p34cdc2; IC50=180 nM) and CDK5 (IC50=100 nM). It reversibly arrests asynchronous HBL-100 cells at G2. Induces apoptosis in the mammary carcinoma cell line MCF-7 (10 µM).
Product Details
| Formula: | C16H11N3O2 |
| |
| MW: | 277.3 |
| |
| CAS: | 160807-49-8 |
| |
| Purity: | ≥98% |
| |
| Appearance: | Dark red solid. |
| |
| Solubility: | Soluble in DMSO (6mg/ml) and ethanol (4mg/ml). |
| |
| Shipping: | Shipped on Blue Ice |
| |
| Long Term Storage: | -20°C |
| |
| Use/Stability: | Stable for at least 1 year after receipt when stored, as supplied, at -20°C. Stock solutions are stable for up to 3 months at -20°C. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
Increased aerobic glycolysis is important for the motility of activated VSMC and inhibited by indirubin-3´-monoxime: E.H. Heiss, et al.; Vascul. Pharmacol.
83, 47 (2016),
Application(s): Cell culture,
Abstract;
Anti-mitotic properties of indirubin-3'-monoxime, a CDK/GSK-3 inhibitor: induction of endoreplication following prophase arrest: E. Damiens, et al.; Oncogene
20, 3786 (2001),
Abstract;
Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?: S. Leclerc, et al.; J. Biol. Chem.
276, 251 (2001),
Abstract;
Inhibition of cyclin-dependent kinase 1 (CDK1) by indirubin derivatives in human tumour cells: D. Marko, et al.; Br. J. Cancer
84, 283 (2001),
Abstract;
Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases: R. Hoessel, et al.; Nat. Cell. Biol.
1, 60 (1999),
Abstract;
